Alzamend Neuro Inc (ALZN) 13F Filings: Institutional Buyers & Sellers (Q2 2026)

ALZN ranks #9638 out of 37503 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

12 institutions disclose a position in ALZN, but none treat it as a major bet — even Kingsbury Capital Investment Advisors LLC, its most concentrated holder, allocates just 1.4% of its own portfolio to it.

UBS Group AG has trimmed its ALZN position for two straight quarters, cutting it by $41.9K while still holding $2.8K.

ALZN is up 3.8% today, and institutions have been net buyers of $2.5M this quarter — today's price move and the underlying institutional flow are pointing the same direction.

ALZN reported a net loss of $8.8M in its latest fiscal year.

• Not yet profitable — net loss of $8.8M in the latest fiscal year
• Net income declined year over year, from -$4.5M to -$8.8M
• Operating cash flow was negative, using $8.1M in cash
• Liabilities run 3167.42x equity — a highly leveraged balance sheet worth noting